Etokimab - AnaptysBio

Drug Profile

Etokimab - AnaptysBio

Alternative Names: ANB020; Anti-IL33-antibody-AnaptysBio; Anti-interleukin-33-antibody-AnaptysBio

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antiallergics; Antibodies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis; Peanut hypersensitivity

Most Recent Events

  • 07 Aug 2018 AnaptysBio plans the phase II ECLIPSE trial for Rhinosinusitis with nasal polyps in by the end of 2018 (SC) (NCT03614923)
  • 29 May 2018 Updated safety and pharmacodynamics data from a phase II trial in Atopic dermatitis released by AnaptysBio
  • 29 May 2018 AnaptysBio plans a phase IIb trial in Peanut hypersensitivity patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top